Not for publication, directly or indirectly, in the United States, South Africa, Australia, Canada or Japan, or any other jurisdiction in which it would be unlawful to do so.
This document is not an offer of securities for sale in the United States. The shares to which this document relates have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will not be a public offering of shares in the United States.
19 May 2020
Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, announces that it has raised total gross proceeds of EUR 535 million following the issuance of 1,000,000 new shares to institutional investors, at a price of EUR 535 per share, representing a 2.5% discount to the 10-day VWAP* on 18 May 2020, and a premium of 1% to the 14-day VWAP since the publication of its Q1 2020 announcement on 28 April 2020.
Following strong investor demand, books were multiple times oversubscribed and Eurofins' management decided to increase the offer size from 900,000 to 1,000,000 new shares. As communicated in yesterday's press release announcing the launch of the equity offering, Eurofins intends to use the net proceeds from the issuance towards supporting its rapid build-up of COVID-19 testing capacities as well as strengthening its capital structure.
Dr. Gilles Martin, Eurofins CEO commented: "The success of this equity issuance demonstrates investors' confidence in our ability to deploy capital to create significant shareholder value. I would like to thank investors for the trust that they have extended over the years, and continue to give to Eurofins. The Board and the executive management of Eurofins intend to continue investing with the same disciplined approach that it has employed in the past, targeting an increase in earnings per share (EPS) that can more than compensate shareholders for the dilution impact from the new issuance."
Berenberg and Credit Suisse acted as Joint Global Coordinators and Joint Bookrunners for the Placement. The settlement-delivery and the admission of the new shares on Euronext Paris (on the same line as Eurofins' existing shares with ISIN code FR0000038259) should occur on 22 May 2020.
*Volume Weighted Average Price
Notes to Editors:
About Eurofins the global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.
This press release does not, and shall not, in any circumstances, constitute a public offering nor an invitation in any jurisdiction in connection with any offer.
In any Member State of the European Economic Area ("EEA"), this press release is only addressed to and directed at persons in Member States who are "qualified investors" within the meaning of Article 2(1)(e) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the "Prospectus Regulation").
This press release has been prepared on the basis that any offer of the new shares in any Member State of the EEA, and in particular in the Grand Duchy of Luxembourg and France, (each, a "Relevant Member State") will be made pursuant to an exemption under the Prospectus Regulation, from the requirement to publish a prospectus. Accordingly any person making or intending to make any offer in that Relevant Member State of securities which are the subject of the placement contemplated in this press release may only do so in circumstances in which no obligation arises for Eurofins Scientific or any of the Joint Bookrunners to publish a prospectus pursuant to Article 3 of the Prospectus Regulation in relation to such offer. Neither Eurofins Scientific nor the Joint Bookrunners have authorized, nor do they authorize, the making of any offer of the new shares in circumstances in which an obligation arises for Eurofins Scientific or any of the Joint Bookrunners to publish prospectus for such offer.
This press release is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.
This press release is an advertisement and not a prospectus for the purposes of Prospectus Regulation.
This press release is not an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Eurofins Scientific does not intend to register any portion of the planned offering in the United States of America or to conduct a public offering of securities in the United States of America.
It may be unlawful to distribute these materials in certain jurisdictions. These materials are not for distribution in the United States, Canada, Japan or Australia. The information in these materials does not constitute an offer of securities for sale in the United States, Canada, Japan or Australia.
Each of the Joint Bookrunners involved in the Placement is acting on behalf of Eurofins Scientific and no one else in connection with any offering of the shares and will not be responsible to any other person for providing the protections afforded to any of its clients or for providing advice in relation to any offering of Eurofins Scientific shares.
The Joint Bookrunners involved in the Placement and certain of their affiliates, have provided and may in the future provide various financing, banking, financial, investment, commercial or other services to Eurofins Scientific or to members of its group, in exchange for which they have received or may receive compensation.
For more information, please visit www.eurofins.com or contact:
Eurofins Scientific SE
Phone: +32 2 766 1620